JP2009532477A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532477A5 JP2009532477A5 JP2009504279A JP2009504279A JP2009532477A5 JP 2009532477 A5 JP2009532477 A5 JP 2009532477A5 JP 2009504279 A JP2009504279 A JP 2009504279A JP 2009504279 A JP2009504279 A JP 2009504279A JP 2009532477 A5 JP2009532477 A5 JP 2009532477A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- region
- sialic acid
- polypeptides
- unpurified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004196 processed proteins & peptides Human genes 0.000 claims 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 229920001184 polypeptide Polymers 0.000 claims 34
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 14
- 238000000034 method Methods 0.000 claims 14
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 14
- 102000003838 Sialyltransferases Human genes 0.000 claims 4
- 108090000141 Sialyltransferases Proteins 0.000 claims 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 238000001042 affinity chromatography Methods 0.000 claims 2
- 238000005571 anion exchange chromatography Methods 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 230000009450 sialylation Effects 0.000 claims 2
- 230000004988 N-glycosylation Effects 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78938406P | 2006-04-05 | 2006-04-05 | |
| US60/789,384 | 2006-04-05 | ||
| PCT/US2007/008396 WO2007117505A2 (en) | 2006-04-05 | 2007-04-03 | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014182741A Division JP2015038086A (ja) | 2006-04-05 | 2014-09-08 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2016114709A Division JP6322849B2 (ja) | 2006-04-05 | 2016-06-08 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009532477A JP2009532477A (ja) | 2009-09-10 |
| JP2009532477A5 true JP2009532477A5 (cg-RX-API-DMAC10.html) | 2010-05-13 |
| JP6084761B2 JP6084761B2 (ja) | 2017-02-22 |
Family
ID=38581601
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504279A Active JP6084761B2 (ja) | 2006-04-05 | 2007-04-03 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2014182741A Pending JP2015038086A (ja) | 2006-04-05 | 2014-09-08 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2016114709A Expired - Fee Related JP6322849B2 (ja) | 2006-04-05 | 2016-06-08 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2018053298A Active JP6686058B2 (ja) | 2006-04-05 | 2018-03-20 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2020065891A Expired - Fee Related JP6989979B2 (ja) | 2006-04-05 | 2020-04-01 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2021192123A Active JP7357382B2 (ja) | 2006-04-05 | 2021-11-26 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014182741A Pending JP2015038086A (ja) | 2006-04-05 | 2014-09-08 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2016114709A Expired - Fee Related JP6322849B2 (ja) | 2006-04-05 | 2016-06-08 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2018053298A Active JP6686058B2 (ja) | 2006-04-05 | 2018-03-20 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2020065891A Expired - Fee Related JP6989979B2 (ja) | 2006-04-05 | 2020-04-01 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2021192123A Active JP7357382B2 (ja) | 2006-04-05 | 2021-11-26 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (14) | US10167332B2 (cg-RX-API-DMAC10.html) |
| EP (3) | EP2815768A3 (cg-RX-API-DMAC10.html) |
| JP (6) | JP6084761B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN101432301B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2007235413B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2647524C (cg-RX-API-DMAC10.html) |
| EA (1) | EA022780B1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL194526A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2008012843A (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ572379A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2007117505A2 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA200808900B (cg-RX-API-DMAC10.html) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080206246A1 (en) * | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| US8470318B2 (en) | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| AU2007235413B2 (en) * | 2006-04-05 | 2012-08-02 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| KR20100107501A (ko) | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | 부위 특이적 접합을 위한 시스테인 조작 항체 |
| JP2011517960A (ja) | 2008-04-22 | 2011-06-23 | ザ ロックフェラー ユニバーシティー | 抗炎症化合物の識別方法 |
| EP2233499A1 (en) | 2009-03-26 | 2010-09-29 | CSL Behring AG | Antibody composition with altered Fab sialylation |
| EP2233502A1 (en) | 2009-03-27 | 2010-09-29 | Deutsches Rheuma-Forschungszentrum Berlin | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them |
| BRPI1015234A2 (en) | 2009-06-22 | 2018-02-20 | Medimmune Llc | fc regions designed for site specific conjugation. |
| US20130058917A1 (en) | 2010-05-07 | 2013-03-07 | Fabian Käsermann | Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column |
| AU2011258425B2 (en) | 2010-05-27 | 2015-12-10 | Merck Sharp & Dohme Llc | Method for preparing antibodies having improved properties |
| AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| EA201892339A3 (ru) | 2011-12-19 | 2019-06-28 | Дзе Рокфеллер Юниверсити | Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания |
| US12384848B2 (en) | 2011-12-19 | 2025-08-12 | The Rockefeller University | Anti-inflammatory polypeptides |
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| WO2014018747A2 (en) | 2012-07-26 | 2014-01-30 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
| CA2909139C (en) | 2013-04-18 | 2021-07-06 | Institut National De La Sante Et De La Recherche Medicale | Composition with reduced immunogenicity |
| EP2991666B1 (en) * | 2013-05-02 | 2020-03-25 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| ES2708759T3 (es) | 2013-05-13 | 2019-04-11 | Momenta Pharmaceuticals Inc | Procedimientos para el tratamiento de la neurodegeneración |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| EP3058084A4 (en) | 2013-10-16 | 2017-07-05 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| EP3149030A2 (en) * | 2014-06-02 | 2017-04-05 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Production of fc fragments |
| CN121021679A (zh) | 2014-10-15 | 2025-11-28 | 芝诺锡拉公司 | 具有降低的免疫原性的组合物 |
| EA202191471A1 (ru) * | 2015-03-04 | 2022-01-31 | Зе Рокфеллер Юниверсити | Противовоспалительные полипептиды |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| EP3493845A4 (en) | 2016-08-03 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY |
| CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
| EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
| EP3658589B1 (en) | 2017-07-26 | 2023-09-27 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
| US20200207867A1 (en) | 2017-09-13 | 2020-07-02 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| EA202091521A1 (ru) | 2017-12-19 | 2020-10-22 | Дзе Рокфеллер Юниверсити | ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ |
| EP3732199A1 (en) | 2017-12-27 | 2020-11-04 | TeneoBio, Inc. | Cd3-delta/epsilon heterodimer specific antibodies |
| IL317993B2 (en) | 2018-07-03 | 2025-11-01 | Gilead Sciences Inc | Antibodies directed against HIV gp120 and methods of use |
| JP2021534769A (ja) | 2018-08-31 | 2021-12-16 | エーエルエックス オンコロジー インコーポレイテッド | デコイポリペプチド |
| SG11202102713TA (en) | 2018-09-21 | 2021-04-29 | Teneobio Inc | Methods for purifying heterodimeric, multispecific antibodies |
| JP2022502466A (ja) * | 2018-10-11 | 2022-01-11 | モメンタ ファーマシューティカルズ インコーポレイテッド | 高度にシリル化されたＩｇＧ組成物による処理 |
| WO2020087065A1 (en) | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| CN110297093B (zh) * | 2019-03-18 | 2022-04-22 | 山西瑞豪生物科技有限公司 | 一种检测人免疫球蛋白g4的方法和试剂盒 |
| KR102549282B1 (ko) * | 2019-11-18 | 2023-06-30 | 건국대학교 산학협력단 | 시알산화된 면역글로불린을 유효성분으로 포함하는 염증성 질환의 치료용 조성물 |
| BR112022011824A2 (pt) | 2019-12-18 | 2022-08-30 | Teneofour Inc | Anticorpos de cadeia pesada que se ligam a cd38 |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| WO2024136368A1 (ko) * | 2022-12-21 | 2024-06-27 | 건국대학교 산학협력단 | α-2,6-시알산화 면역글로불린의 안구 건조증 또는 염증성 안과 질환의 예방 또는 치료 용도 |
| CN115819560A (zh) * | 2022-12-27 | 2023-03-21 | 河南赛诺特生物技术有限公司 | 制备第二抗体的方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| FR2556219B1 (fr) * | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5047335A (en) * | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| AU656934B2 (en) * | 1990-11-23 | 1995-02-23 | General Hospital Corporation, The | Inhibition of cell adhesion protein-carbohydrate interactions |
| US5453272A (en) | 1992-10-02 | 1995-09-26 | Alberta Research Council | Lectin derived carbohydrate binding-peptide |
| US5707622A (en) * | 1994-03-03 | 1998-01-13 | Genentech, Inc. | Methods for treating ulcerative colitis |
| US6656466B1 (en) | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
| US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| US20020045207A1 (en) | 1997-10-31 | 2002-04-18 | Lynne A. Krummen | Glycoprotein production process |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| ES2378272T3 (es) * | 1999-04-15 | 2012-04-10 | Crucell Holland B.V. | Producción de proteína recombinante en una célula humana |
| DE19927835A1 (de) * | 1999-06-18 | 2000-12-21 | Clariant Gmbh | Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten |
| US7064191B2 (en) * | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| JPWO2002030954A1 (ja) | 2000-10-06 | 2004-02-19 | 協和醗酵工業株式会社 | 抗体を精製する方法 |
| EP1370288B1 (en) | 2000-11-20 | 2012-01-11 | Canadian Blood Services | Method for treating thrombocytopenia with monoclonal ivig |
| US7473680B2 (en) | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
| US7427469B2 (en) * | 2002-11-05 | 2008-09-23 | Institut Pasteur | Method of treating cytomegalovirus with DC-SIGN blockers |
| TWI328614B (en) * | 2002-12-23 | 2010-08-11 | Bristol Myers Squibb Co | Product quality enhancement in mammalian cell culture processes for protein production |
| US20070048740A1 (en) * | 2003-02-14 | 2007-03-01 | Research Association For Biotechnology | Full-length cDNA |
| ME00426B (me) * | 2003-04-09 | 2011-10-10 | Genentech Inc | Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor |
| JP2007528195A (ja) | 2003-10-09 | 2007-10-11 | デウン カンパニー，リミテッド | 高シアル酸含量のヒトトロンボポエチンを精製する方法 |
| HUE038955T2 (hu) * | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| AU2004299053B2 (en) * | 2003-12-15 | 2011-01-06 | Alexion Pharmaceuticals, Inc. | Novel anti-DC-SIGN antibodies |
| EP1699821B1 (en) * | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| CN101506238B (zh) * | 2005-06-30 | 2013-11-06 | 森托科尔公司 | 具有提高治疗活性的方法和成分 |
| WO2007024743A2 (en) * | 2005-08-19 | 2007-03-01 | Centocor, Inc. | Proteolysis resistant antibody preparations |
| AU2006312148B2 (en) | 2005-11-07 | 2012-04-12 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| WO2008057634A2 (en) | 2006-10-26 | 2008-05-15 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| US20080206246A1 (en) * | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| US8470318B2 (en) * | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| AU2007235413B2 (en) * | 2006-04-05 | 2012-08-02 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| KR101627157B1 (ko) | 2007-12-27 | 2016-06-03 | 박스알타 인코퍼레이티드 | 샘플 내의 재조합 단백질로부터 혈장-유래 단백질의 분별 방법 |
-
2007
- 2007-04-03 AU AU2007235413A patent/AU2007235413B2/en active Active
- 2007-04-03 CN CN200780015563.6A patent/CN101432301B/zh active Active
- 2007-04-03 EP EP14183260.0A patent/EP2815768A3/en not_active Ceased
- 2007-04-03 MX MX2008012843A patent/MX2008012843A/es active IP Right Grant
- 2007-04-03 CA CA2647524A patent/CA2647524C/en active Active
- 2007-04-03 US US12/294,883 patent/US10167332B2/en active Active
- 2007-04-03 EP EP18188349.7A patent/EP3456351A1/en not_active Withdrawn
- 2007-04-03 EP EP07754846.9A patent/EP2010566B2/en active Active
- 2007-04-03 NZ NZ572379A patent/NZ572379A/en not_active IP Right Cessation
- 2007-04-03 JP JP2009504279A patent/JP6084761B2/ja active Active
- 2007-04-03 EA EA200870411A patent/EA022780B1/ru unknown
- 2007-04-03 WO PCT/US2007/008396 patent/WO2007117505A2/en not_active Ceased
-
2008
- 2008-10-05 IL IL194526A patent/IL194526A/en active IP Right Grant
- 2008-10-17 ZA ZA200808900A patent/ZA200808900B/xx unknown
-
2013
- 2013-05-16 US US13/896,070 patent/US20130273040A1/en not_active Abandoned
-
2014
- 2014-05-16 US US14/280,181 patent/US20140323696A1/en not_active Abandoned
- 2014-09-08 JP JP2014182741A patent/JP2015038086A/ja active Pending
-
2015
- 2015-02-17 US US14/624,483 patent/US20160176950A1/en not_active Abandoned
-
2016
- 2016-06-08 JP JP2016114709A patent/JP6322849B2/ja not_active Expired - Fee Related
- 2016-10-07 US US15/288,764 patent/US20170088608A1/en not_active Abandoned
-
2017
- 2017-04-20 US US15/492,987 patent/US20170218050A1/en not_active Abandoned
- 2017-06-21 US US15/629,056 patent/US20170283492A1/en not_active Abandoned
- 2017-06-21 US US15/629,119 patent/US20170320935A1/en not_active Abandoned
-
2018
- 2018-03-20 JP JP2018053298A patent/JP6686058B2/ja active Active
- 2018-09-28 US US16/145,688 patent/US20190031737A1/en not_active Abandoned
- 2018-10-02 US US16/150,058 patent/US20190031738A1/en not_active Abandoned
-
2019
- 2019-01-10 US US16/245,053 patent/US20190127446A1/en not_active Abandoned
- 2019-12-20 US US16/724,137 patent/US20200385443A1/en not_active Abandoned
-
2020
- 2020-04-01 JP JP2020065891A patent/JP6989979B2/ja not_active Expired - Fee Related
- 2020-12-14 US US17/121,622 patent/US20210101961A1/en not_active Abandoned
-
2021
- 2021-11-26 JP JP2021192123A patent/JP7357382B2/ja active Active
-
2022
- 2022-12-20 US US18/085,190 patent/US20230121427A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vollet Marson et al. | Membrane fractionation of protein hydrolysates from by-products: recovery of valuable compounds from spent yeasts | |
| Chollangi et al. | Development of robust antibody purification by optimizing protein‐A chromatography in combination with precipitation methodologies | |
| Nagae et al. | Function and 3D structure of the N-glycans on glycoproteins | |
| Gronemeyer et al. | Trends in upstream and downstream process development for antibody manufacturing | |
| JP2011506476A5 (cg-RX-API-DMAC10.html) | ||
| Ligtenberg et al. | Deleted in malignant brain tumors-1 protein (DMBT1): a pattern recognition receptor with multiple binding sites | |
| JP2010512306A5 (cg-RX-API-DMAC10.html) | ||
| FI3368555T3 (fi) | Kaksitoimisia proteiineja ja niitä sisältävä farmaseuttinen koostumus | |
| Petrou et al. | IgA nephropathy: current treatment and new insights | |
| Gasparini et al. | Thermally-induced lactosylation of whey proteins: Identification and synthesis of lactosylated β-lactoglobulin epitope | |
| JP2006513978A5 (cg-RX-API-DMAC10.html) | ||
| Gallaher et al. | Modeling of the Ebola virus delta peptide reveals a potential lytic sequence motif | |
| JP2017505620A5 (cg-RX-API-DMAC10.html) | ||
| JP2009508476A5 (cg-RX-API-DMAC10.html) | ||
| CN109843904A (zh) | 用于降低治疗性蛋白的异质性的连续方法 | |
| ES2708759T3 (es) | Procedimientos para el tratamiento de la neurodegeneración | |
| Kim et al. | Functional expression of the recombinant spike receptor binding domain of SARS-CoV-2 Omicron in the periplasm of Escherichia coli | |
| Esqueda et al. | A monoclonal antibody produced in glycoengineered plants potently neutralizes monkeypox virus | |
| Sakai et al. | Construction of recombinant hemagglutinin derived from the gingipain-encoding gene of Porphyromonas gingivalis, identification of its target protein on erythrocytes, and inhibition of hemagglutination by an interdomain regional peptide | |
| Li et al. | Enhanced downstream processing for a cell-based avian influenza (H5N1) vaccine | |
| Kajihara et al. | Chemical synthesis of homogeneous glycopeptides and glycoproteins | |
| JP2016535071A5 (cg-RX-API-DMAC10.html) | ||
| Xu et al. | Advances in novel biologics targeting BAFF/APRIL in the treatment of IgA nephropathy | |
| Karuppanan et al. | Expression, purification, and biophysical characterization of a secreted anthrax decoy fusion protein in Nicotiana benthamiana | |
| Xie et al. | Discovery of an orally effective factor IX-transferrin fusion protein for hemophilia B |